Key Points: RARα2 activates Wnt and hedgehog pathways in maintaining myeloma stem cell features and drug resistance.
Introduction
Cancer stem cells (CSC) have been identified in multiple malignancies, 1,2 including MM. 3 Besides the distinctive properties of constituting a small fraction of tumor cells with self-renewal capacity, able to propagate the disease, CSCs are thought to be, just like hematopoietic stem cells, much more resistant to chemo-and radiotherapy, to have better DNA repair mechanisms and increased anti-apoptotic activity. 1, 2, 4 Evidence of the existence of a MM stem cell has been provided by Matsui et al. showing that the CD138 -/CD19 + fraction has a greater clonogenic potential and has the phenotype of a memory B-cell (CD19 + , CD27 + ). 3 The CD138 -cell fraction contains significantly higher levels of aldehyde dehydrogenase (ALDH), a marker for stem cells. 
CD138
-cells are resistant to cyclophosphamide, dexamethasone, bortezomib and lenalidomide, while the CD138 + fraction is sensitive to these drugs. 3, 5 The CD138 -/CD19 + cells in the MM bone marrow are surface and cytoplasmic light chain-restricted (LCR). 6 However, not all researchers agree on the MMSC phenotype. The
Weissman group considers the CD19 -/CD45 low/-/CD38 high /CD138 + cells to be the tumor-initiating cells in myeloma. 7 Also, the Dana-Farber group found no correlation between the side population (SP) cells, which are enriched for cancer stem cells and CD138 expression. 8 We have previously reported that the 30% of newly diagnosed myeloma patients, who expressed the retinoic acid receptor alpha2 (RARα2) in their CD138 selected plasma cells, had a significantly inferior outcome.
9
RARα2 expression was also highly significantly increased in myelomas rapidly relapsing after transplantation, compared with paired baseline samples. 9 These findings strongly suggest the existence at diagnosis of a RARα2 expressing drug-resistant subclone, which can be CD138 + . Retinoic acid (RA) is a non-hormonal ligand for the nuclear receptor (NR), and it is a biologically active form of vitamin A. There are two major isoforms for RARα (α1 and was present in limited number of tissues such as intestine, lung and liver. 10 Furthermore, RARα2 is a more
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Very little is known about the genetic make-up of cancer stem cells, which makes it difficult to target such cells.
However, the Hedgehog (Hh) pathway, Wnt signaling, Notch and BMI-1 are typically active in cancer stem cells. 1, [14] [15] [16] [17] [18] [19] The Matsui group has demonstrated that Hh signaling maintains the tumor stem cell compartment in myeloma. 20 MM cells have also been reported to depend on an active Wnt signaling; epigenetic dysregulation of Wnt signaling pathways resulted in promoting MM cell proliferation, migration, invasion and drug-resistance. [21] [22] [23] In the present work, we find increased RARα2 expression in MMSC and explore its function in inducing drug resistance and maintaining MM stem cell features. The association of RARα2 and its down-stream targets with drug resistance is assessed using in vivo and in vitro myeloma models.
Methods

Cell lines, patient samples, and cell culture
Human MM cell lines were cultured in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS) at 37°C in humidified 5% CO2.
9,24-26
The details were described in the Supplemental Data.
Clinical bone marrow samples were obtained from MM patients in Huntsman Cancer Institute, University of Utah according to the ARUP protocol 25009. Studies are approved by the Institutional Review Board of the University of Utah. Informed consent was obtained in accordance with the Declaration of Helsinki.
CD138
+ or CD138 -subsets were isolated from MM cell lines using autoMACS and CD138 microbeads.
Subsequent flow cytometric analysis demonstrated less than 5% contamination.
Gene Expression Profiling (GEP)
Gene expression profiling, using the Affymetrix HuGene-1_0-st-v1 microarray, was performed as previously described ans see Supplemental Data. 27, 28 The Gene Expression Omnibus database accession number perfomed on paired MM cell line samples in this paper is GSE46816.
For personal use only. on May 10, 2017 . by guest www.bloodjournal.org From
Specific gene silencing or overexpressing RARα2 in MM cells by lentivirus expression vector system
Specific gene knockdown was performed as previously described. 25, 29 Similar methods were used to overexpress RARα2 in ARP1 and OCI-MY5, and knockdown RARα2 in ARK and KMS11.
Co-immunoprecipitation (Co-IP)
Co-IP was performed as described previously 30 . Briefly, HEK-293 cells were transiently co-transfected with plasmids containing a 3X FLAG tag (RARα2) or a V5 tag (Nanog) at the C-terminus of the protein using Lipofectamine. Endogenous protein interaction was verified in RARα2 overexpressing myeloma cell line OCI-MY5. Benzonase (150U/ml, Milipore, MA) was added to the OCI-MY5 cell lysate to exclude the possibility of chromatin-mediated protein interaction. Specific antibodies or control IgG (Bethyl Laboratories) were added and incubated overnight with cell lysate followed by protein dynabeads for 2 hrs at 4 °C. The pulled down proteins were extracted and examined by Western blots as described before.
Flow-cytometry analysis
Aldehyde dehydrogenase (ALDH) activity was tested by the Aldefluor reagent (Stem Cell Technologies, Vancouver, Canada) according to manufacturer's instructions. Diethylaminobenzaldehyde (DEAB) was used as control staining. The side population analysis was conducted as previously described. 8 Briefly, Hoechst (10μg/mL) was incubated with cells (10 6 cells/mL) in the 37°C water bath for 90 minutes. Verapamil (100μM) was used as negative control.
For the apoptosis and multidrug-resistance assays, all the procedures were performed as described in the protocols (Annexin V Apoptosis Detection Kit APC, eBioscience; eFluxx-ID™ Multidrug resistance assay kits, Enzo Life Sciences) as previously reported.
24
Clonogenic formation assay
Colony formation was performed as previous reported. 24 Briefly, 10,000 MM cells were seeded in 0.33% agar cultures. The colonies were fed with medium in the presence or absence of drugs; after 3 weeks the plates were imaged and colony numbers were counted by ImageJ. 
Results
RARα2 expression is significantly higher in myeloma stem cells than in bulk of myeloma cells
To clarify the characteristics of the CD138 + and CD138 -cells, these fractions were separated from ARK and KMS11 MM cell lines and the differences in growth were evaluated in short-term cultures for 5 days. The CD138 + cells showed significantly higher cell growth compared with CD138 -cells ( Figure 1A ; p < 0.05). Gene expression profiling (GEP) analyses were performed on the CD138 + and CD138 -cells isolated from 8 MM cell lines. A total of 291 genes were significantly differentially expressed in the CD138 -cell population compared with CD138 + control cells (p < 0.05), including 209 up-regulated genes and 82 down-regulated genes ( Figure   1B ) and the order of differentially expressed genes between CD138 + with CD138 -fraction in 8 MM Cells is provided in Table S1 . Consistent with increased cell proliferation characteristics of CD138 + myeloma cells, many genes, significantly down-regulated in CD138 -cells, were related to DNA replication, cell cycle progression, and chromosomal stability suggesting that the CD138 + cells are more proliferative, whereas the CD138 -cells are more quiescent. In addition, the CD138 + and CD138 -fractions from ARP1, KMS28PE and For personal use only. on May 10, 2017. by guest www.bloodjournal.org From
Increased RARα2 expression induces stem cell characteristics in MM
To assess whether RARα2 was indeed the driver rather than an associated phenomenon of drug resistance and stem cell features, we over-expressed RARα2 in bulk cells of low-expressing MM cell lines of ARP1 and OCI-MY5 (Figure 2A) . ALDH is a marker of cancer stem cells and a predictor of drug resistance in multiple cancers. 32, 33 We examined ALDH activity in RARα2 over-expressing ARP1 and OCI-MY5 cells using the fluorescent ALDH substrate Aldefluor and western blot analysis. ALDH expression and activity significantly increased in RARα2 over-expressing ARP1 and OCI-MY5 compared with the control cells (Figure 2A & 2B) .
The frequency of side population (SP) cells in ARP1 and OCI-MY5 MM cell lines was also significantly increased to 1.09% in OCI-MY5 cells and 0.71% in ARP1 cells compared with the empty vector-transfected control cells (p < 0.05) ( Figure 2C ).
RARα2 upregulates and physically binds with reprogramming genes essential for pluripotent stem cells (iPS), and promotes colony formation in MM cell lines
The property of self-renewal is shared by iPS and cancer stem cells. We found that overexpression of RARα2 in The clonogenic capacity of ARP1 and OCI-MY5 cells was significantly increased by RARα2 over-expression compared with the EV controls ( Figure 3E) . The colony formation rate of ARP1 cells increased from 9% to 13% after RARα2 was over-expressed while it rose from 9% to 12% in OCI-MY5 cells (p < 0.05). Figure 5B ; p < 0.05).
To explain this observed drug resistance, The eFluxx-ID™ Multidrug resistance assay was performed and showed that over-expression of RARα2 increased drug-resistance by increasing MRP expression in both ARP1
and OCI-MY5 cells compared to the control cells ( Figure 5C ). To further confirm this finding, we examined the expression of the multi-drug resistance genes ABCG2, ABCB1, ABCC1 and ABCC3 using western blots. As shown in Figure 5D , the expression of ABCC3 (MRP3) was significantly increased in ARP1 and OCI-MY5 over-expressing RARα2, whereas the expression of ABCG2, ABCB1 an ABCC1 remained unchanged (data not shown). In addition, the expression of ABCC3 decreased in the RARα2-silenced ARK and KMS11cells ( Figure   5E ).
We subsequently examined the expression of Bcl-2 family genes Bcl-2, Bcl-xl, Mcl-1, Bad, Bax and Puma, which have been associated with drug resistance in CSC. As shown in Figure 6A , the expression of Bcl-2 and
Mcl-1 were significantly increased in ARP1 and OCI-MY5 over-expressing RARα2, whereas the expression the other Bcl-2 family members mentioned above remained unchanged (data not shown). In addition, the expression of Bcl-2 and Mcl-1 decreased in the RARα2-silenced ARK and KMS11 cells ( Figure 6B ).
RARα2-overexpressing cells ARP1 and OCI-MY5 were treated for 24 hours with the Cox-2 inhibitor (CAY10404, 10μM), which down-regulates the Wnt pathway in several tumors [34] [35] [36] . Using the eFluxx-ID™ Multidrug resistance assay, flow cytometry showed that CAY10404 decreased the activity of the efflux pump induced by RARα2 ( Figure 6C) . Interestingly, an inhibitor of the MRP3 transporter (MK571, 20nM) could not alter the RARα2 induced drug resistance by itself; however, the combination of MK571 and bortezomib (5nM) significantly inhibited colony formation in the RARα2-overexpressing cells ( Figure 6D ).
Targeting MMSCs through inhibition of Wnt and Hh signaling in vitro in human MM cell lines and in the 5TGM1 myeloma mouse model
For personal use only. on May 10, 2017. by guest www.bloodjournal.org From Since over-expression of RARα2 in RARα2 low-expressing cell lines activates both the Wnt and Hh signaling pathway activity, we subsequently evaluated the effects of ATRA, CAY10404 and the Hh inhibitor (cyclopamine) on ARP1 and OCI-MY5 cells over-expressing RARα2, using the colony formation assay. ARP1 and OCI-MY5 cells over-expressing RARα2 were treated with or without ATRA (1nM, 10nM) or CAY10404 (1nM, 10nM) or cyclopamine (1nM, 10nM) for two weeks. As shown in Figure 7A , all three drugs inhibited significantly the colony formation of RARα2-overexpressing MM cells even at low concentrations. To further demonstrate that RARα2 plays an important role in maintaining MMSC "stemness" through activating Wnt and Hh signaling, real-time PCR was performed and showed that the expression levels of RARα2 and levels of other showed a significant shorter survival than those injected with bulk MM cells (CD138 + ) (p < 0.05)( Figure 7D ).
Treatment with cyclopamine or CAY10404 significantly extended mice survival (p < 0.05) ( Figure 7D ) and decreased tumor progression as measured by serum IgG2B levels ( Figure 7E ). In addition, we found that another Hh inhibitor, itraconazole (20mg/kg, I.P.), was equally effective as cyclopamine in suppressing the growth of 5TGM1 cells in vivo.
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Discussion
Most of our myeloma therapies exert their effects on the more differentiated and more drug-sensitive myeloma cells. These therapies take advantages of key features of malignant cells, i.e., they proliferate faster than normal cells, or they disrupt pathways and stromal interactions required for the survival of these more mature myeloma cells. In our opinion, there are currently no effective approaches available to deal with MMSCs (non-cycling, highly drug-resistant MM cells), except for high dose chemotherapy with drugs that are lethal to hematopoietic stem cells. The combination of ASCT with the newer drugs such as bortezomib, thalidomide and lenalidomide, has greatly improved the clinical outcome of MM patients, with median 5-year progression-free survivals of > 50% and median overall survival of more than 10 years. 37 However, these agents still fail to completely eradicate the disease in many patients, most likely because of the persistence of a MMSC compartment, which survives myelo-ablative therapy. Therefore, a specific post-transplant therapy is needed to directly hit these virtually non-cycling MMSCs.
In this study, we have demonstrated that CD138 -myeloma cells had high expression of RARα2, and showed that artificial over-expression of RARα2 induced the typical features of stem cells, such as increased side population cells, increased clonogenesic potential and drug-resistance, increased expression of prototypical stem cell genes, and activation of signaling pathways typically observed in CSC. The opposite effect was seen when RARα2 was knocked-down. Also, RARα2 expression was significantly increased in CD138 selected myeloma cells at relapse compared with those at diagnosis. 9 We performed quantitative real-time PCR analysis to examine RARα2 expression in MM cell lines and a peripheral blood sample from a MM patient, and found higher levels of RARα2 in the CD138 -fraction of MM cell lines and SP/κ + fraction in primary sample compared to non-SP/κ + cells. We had previously shown that newly diagnosed MM patients with high baseline expression of RARα2 in CD138 selected myeloma cells, had an inferior outcome 9 . We now found that RARα2 expression in CD138 selected myeloma cells was positively correlated with Oct4, Sox2, Nanog, Lin28A, TCF1, CCND1 and ABCC3 expression in 23 primary myeloma samples (p < 0.05), explaining the poor prognosis of these patients.
These observations strongly suggest that RARα2 may play a crucial role in maintaining MM stem cell features.
Moreover, we observed that over-expression of RARα2 induced drug resistance by increasing levels of ALDH.
We found that RARα2 interacts with Nanog which is essential for ES and iPS cell pluripotency and maintaining 14,38 Therefore, we also probed the Hh genes in MMSCs, and found that Gli1 and SMO showed higher levels of expression in RARα2 over-expressing cells. The ABC transporter members are direct targets of β -catenin. 39 Thus, increased levels of nuclear β -catenin were associated with increased expression of the ABCC3 gene. Moreover, Nanog co-localizes with endogenous nuclear β -catenin in colorectal cancer cells and defines colon cancer stem cells. 40 It is known that β -catenin inhibits Tcf3-mediated repression of Nanog, and activates targets together with Tcf1 to collectively facilitate ES cell self-renewal. 41 Additionally, β -catenin interacts with and stabilizes Oct4 in a TCF independent manner as an alternative strategy to enhance the pluripotent stem cell state. 42 We propose that RARα2, in collaboration with stabilized β -catenin, can activate the core pluripotency factor Nanog. Our analyses of published chromatin occupancy experiments 43 demonstrate that these proteins, together with accessory pluripotency factors such as Myc and Klf4, bind the promoters and regulatory elements of target genes such as CCND1 and CD44, thereby enabling a mechanism for propagating the MMSC state.
We used ATRA, a physiologically active derivative of vitamin A, to inhibit the over-expressed RARα2 receptor, and CAY10404, one of the most selective inhibitors of Cox-2, to block the Wnt pathway in MMSCs.
Cyclopamine is a well-known SMO antagonist and prevents the accumulation of SMO in the Hh pathway. 20, 44 We utilized CAY10404 and cyclopamine to target both the Wnt and Hh pathways and evaluated the efficacy of MMSC inhibition in vitro and in vivo. We also discovered that itraconazole, another Hh inhibitor, showed a clear effect on mouse survival similar to that of cyclopamine.
In conclusion, this study demonstrates that RARα2 plays a crucial role in MMSCs, and it activates Wnt and Hh pathways, possibly by regulating the transcription of Nanog and other stem cell genes, thereby maintaining the stem cell state of these cells ( Figure 7F ). For personal use only. on May 10, 2017. by guest www.bloodjournal.org From
